Endocrine Society Updates Osteoporosis Clinical Practice Guideline
New recommendations include romosozumab therapy for high risk patients The Endocrine Society today announced an update to its osteoporosis Clinical Practice Guideline to include recommendations for romosozumab, a new medication that was approved last year to treat postmenopausal women at high risk of fracture. The U.S. Food and Drug Administration approved romosozumab in April 2019,...